Provided by Tiger Trade Technology Pte. Ltd.

Ligand Pharmaceuticals

280.18
-6.1100-2.13%
Post-market: 280.180.00000.00%19:30 EDT
Volume:158.24K
Turnover:44.66M
Market Cap:5.59B
PE:28.85
High:286.27
Open:286.27
Low:279.87
Close:286.29
52wk High:326.63
52wk Low:157.52
Shares:19.94M
Float Shares:19.35M
Volume Ratio:0.86
T/O Rate:0.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):9.71
EPS(LYR):6.13
ROE:21.96%
ROA:3.99%
PB:5.77
PE(LYR):45.71

Loading ...

Sep 27, 2023

Major Issues Report

Form 8-K - Current report
Sep 18, 2023

Major Issues Report

Form 8-K - Current report
Aug 09, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 08, 2023

Major Issues Report

Form 8-K - Current report
Jun 09, 2023

Major Issues Report

Form 8-K - Current report
May 16, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 10, 2023

Proposed Sale Of Securities

144 - Report of proposed sale of securities
May 08, 2023

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 08, 2023

Proposed Sale Of Securities

144 - Report of proposed sale of securities
May 04, 2023

Major Issues Report

8-K - Current report
Mar 30, 2023

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Mar 13, 2023

Major Issues Report

8-K - Current report
Feb 28, 2023

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 22, 2023

Major Issues Report

8-K - Current report
Feb 09, 2023

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Feb 09, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 09, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Dec 14, 2022

Major Issues Report

8-K - Current report
Dec 05, 2022

Major Issues Report

8-K - Current report
Nov 08, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]